{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:18:54Z","timestamp":1791245934823,"version":"4.1.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003243","name":"Ministerstvo Zdravotnictv\u00c3\u00ad Cesk\u00c3\u00a9 Republiky","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003243","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Genetics"],"published-print":{"date-parts":[[2013,1]]},"DOI":"10.1016\/j.cancergen.2012.12.003","type":"journal-article","created":{"date-parts":[[2013,1,9]],"date-time":"2013-01-09T22:46:09Z","timestamp":1357771569000},"page":"26-31","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":57,"title":["The dominant role of G12C over other KRAS mutation types in the negative prediction of efficacy of epidermal growth\u00a0factor receptor tyrosine kinase inhibitors in non\u2013small cell\u00a0lung cancer"],"prefix":"10.1016","volume":"206","author":[{"given":"Ondrej","family":"Fiala","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milos","family":"Pesek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jindrich","family":"Finek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucie","family":"Benesova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbora","family":"Belsanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marek","family":"Minarik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cancergen.2012.12.003_bib1","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1056\/NEJMoa040938","article-title":"Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib","volume":"350","author":"Lynch","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cancergen.2012.12.003_bib2","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1126\/science.1099314","article-title":"EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy","volume":"304","author":"Paez","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.cancergen.2012.12.003_bib3","doi-asserted-by":"crossref","first-page":"497","DOI":"10.18632\/oncotarget.186","article-title":"EGFR-mutated lung cancer: a paradigm of molecular oncology","volume":"1","author":"Zhang","year":"2010","journal-title":"Oncotarget"},{"key":"10.1016\/j.cancergen.2012.12.003_bib4","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1200\/JCO.2006.07.3585","article-title":"Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer","volume":"25","author":"Sequist","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cancergen.2012.12.003_bib5","doi-asserted-by":"crossref","first-page":"148","DOI":"10.3816\/CLC.2009.n.020","article-title":"Individualizing therapy for non-small-cell lung cancer: a paradigm shift from empiric to integrated decision-making","volume":"10","author":"Gandara","year":"2009","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.cancergen.2012.12.003_bib6","doi-asserted-by":"crossref","first-page":"S1029","DOI":"10.1097\/JTO.0b013e3181b27170","article-title":"Molecular analysis-based treatment strategies for the management of non-small cell lung cancer","volume":"4","author":"West","year":"2009","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cancergen.2012.12.003_bib7","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S1556-0864(15)31506-9","article-title":"The Ras\/Raf\/MAPK pathway","volume":"1","author":"Molina","year":"2006","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cancergen.2012.12.003_bib8","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/nrc1097","article-title":"RAS oncogenes: the first 30 years","volume":"3","author":"Malumbres","year":"2003","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.cancergen.2012.12.003_bib9","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1245\/s10434-009-0811-z","article-title":"KRAS mutation in colon cancer: a marker of resistence to EGFR-I therapy","volume":"4","author":"Siddiqui","year":"2010","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.cancergen.2012.12.003_bib10","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1126\/science.6695174","article-title":"Malignant activation of a K-RAS oncogene in lung carcinoma but not in normal tissue of the same patient","volume":"223","author":"Santos","year":"1984","journal-title":"Science"},{"key":"10.1016\/j.cancergen.2012.12.003_bib11","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s10555-010-9209-4","article-title":"Biological and clinical significance of KRAS mutations in lung cancer: an oncogenic driver that contrasts with EGFR mutation","volume":"29","author":"Suda","year":"2010","journal-title":"Cancer Metastasis Rev"},{"key":"10.1016\/j.cancergen.2012.12.003_bib12","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1056\/NEJM198710083171504","article-title":"Mutational activation of the K-RAS oncogene: a possible pathogenetic factor in adenocarcinoma af the lung","volume":"317","author":"Rodenhuis","year":"1987","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cancergen.2012.12.003_bib13","first-page":"1305","article-title":"The role of KRAS mutations in resistance to EGFR inhibition in the treatment of cancer","volume":"10","author":"Lopez-Chavez","year":"2009","journal-title":"Curr Opin Investig Drugs"},{"key":"10.1016\/j.cancergen.2012.12.003_bib14","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1038\/nature07423","article-title":"Somatic mutations affect key\u00a0pathways in lung adenocarcinoma","volume":"455","author":"Ding","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.cancergen.2012.12.003_bib15","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1093\/jnci\/83.14.1024","article-title":"Relationship between K-RAS oncogene activation and smoking in adenocarcinoma of the human lung","volume":"83","author":"Slebos","year":"1991","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.cancergen.2012.12.003_bib16","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1002\/1097-0142(20010915)92:6<1525::AID-CNCR1478>3.0.CO;2-H","article-title":"Cigarette smoking is strongly associated with mutation of the K-RAS gene in patients with primary adenocarcinoma of the lung","volume":"92","author":"Ahrendt","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/j.cancergen.2012.12.003_bib17","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1593\/neo.09814","article-title":"Clinical implications of KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors: an important role for mutations in minor clones","volume":"11","author":"Marchetti","year":"2009","journal-title":"Neoplasia"},{"key":"10.1016\/j.cancergen.2012.12.003_bib18","doi-asserted-by":"crossref","first-page":"5900","DOI":"10.1200\/JCO.2005.02.857","article-title":"Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib","volume":"23","author":"Eberhard","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cancergen.2012.12.003_bib19","first-page":"5121","article-title":"Prognostic and predictive implications of EGFR mutations, EGFR copy number and KRAS mutations in advanced stage lung adenocarcinoma","volume":"30","author":"Bonanno","year":"2010","journal-title":"Anticancer Res"},{"key":"10.1016\/j.cancergen.2012.12.003_bib20","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1097\/JTO.0b013e3181e2f4d6","article-title":"Prognostic implications of epidermal growth factor receptor and KRAS gene mutations and epidermal growth factor receptor gene copy numbers in patients with surgically resectable non-small cell lung cancer in Taiwan","volume":"5","author":"Liu","year":"2010","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cancergen.2012.12.003_bib21","doi-asserted-by":"crossref","first-page":"4268","DOI":"10.1200\/JCO.2007.14.8924","article-title":"Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21","volume":"26","author":"Zhu","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cancergen.2012.12.003_bib22","doi-asserted-by":"crossref","first-page":"5034","DOI":"10.1200\/JCO.2006.06.3958","article-title":"Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer","volume":"24","author":"Hirsch","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cancergen.2012.12.003_bib23","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1200\/JCO.2009.24.3030","article-title":"Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial","volume":"28","author":"Douillard","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cancergen.2012.12.003_bib24","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S1470-2045(10)70112-1","article-title":"Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study","volume":"11","author":"Cappuzzo","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cancergen.2012.12.003_bib25","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1200\/jco.2009.27.15_suppl.8020","article-title":"Biomarker analyses from the phase III placebo-controlled SATURN study of maintenance erlotinib following first-line chemotherapy for advanced NSCLC","volume":"27","author":"Brugger","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cancergen.2012.12.003_bib26","first-page":"2767","article-title":"Dominance of EGFR and insignificant KRAS mutations in prediction of tyrosine-kinase therapy for NSCLC patients stratified by tumor subtype and smoking status","volume":"29","author":"Pesek","year":"2009","journal-title":"Anticancer Res"},{"key":"10.1016\/j.cancergen.2012.12.003_bib27","first-page":"96","article-title":"Impact of EGFR and KRAS mutations on survival prognosis of NSCLC patients treated with tyrosin-kinase inhibitors: comparison of gefitinib and erlotinib","volume":"69","author":"Minarik","year":"2009","journal-title":"Stud Pheumol Phthiseol"},{"key":"10.1016\/j.cancergen.2012.12.003_bib28","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1093\/jnci\/90.9.675","article-title":"Kirsten ras Mutations in Patients With Colorectal Cancer: the Multicenter \u201cRASCAL\u201d Study","volume":"90","author":"Andreyev","year":"1998","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.cancergen.2012.12.003_bib29","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.3892\/or_00000352","article-title":"Different types of K-RAS mutations are conversely associated with overall survival in patients with colorectal cancer","volume":"21","author":"Winder","year":"2009","journal-title":"Oncol Rep"},{"key":"10.1016\/j.cancergen.2012.12.003_bib30","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1002\/path.995","article-title":"Differences in in\u00a0vitro invasive capacity induced by differences in Ki-Ras protein station","volume":"195","author":"Al Mulla","year":"2001","journal-title":"J\u00a0Pathol"},{"key":"10.1016\/j.cancergen.2012.12.003_bib31","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/(SICI)1096-9896(199903)187:4<433::AID-PATH273>3.0.CO;2-E","article-title":"Structural Differences between valine-12 and aspartate-12 Ras proteins\u00a0may modify carcinoma aggression","volume":"187","author":"Al Mulla","year":"1999","journal-title":"J\u00a0Pathol"},{"key":"10.1016\/j.cancergen.2012.12.003_bib32","doi-asserted-by":"crossref","first-page":"5901","DOI":"10.1158\/0008-5472.CAN-10-0192","article-title":"Genomic and biological characterization of exon 4 KRAS mutations in human cancer","volume":"70","author":"Janakiraman","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.cancergen.2012.12.003_bib33","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1093\/annonc\/mdq680","article-title":"Different types of K-Ras mutations could affect drug sensitivity and tumour behavior in non-small-cell lung cancer","volume":"22","author":"Garassino","year":"2011","journal-title":"Ann Oncol"},{"issue":"Supplement 8","key":"10.1016\/j.cancergen.2012.12.003_bib34","article-title":"Sorafenib activity in NSCLC cell lines seems related to a different type of K-RAS mutations","volume":"21","author":"Broggini","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cancergen.2012.12.003_bib35","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1093\/jnci\/djr523","article-title":"Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome","volume":"104","author":"Ihle","year":"2012","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.cancergen.2012.12.003_bib36","first-page":"1667","article-title":"Multiplicity of EGFR and KRAS mutations in non-small cell lung cancer (NSCLC) patients treated with tyrosine kinase inhibitors","volume":"30","author":"Benesova","year":"2010","journal-title":"Anticancer Res"},{"key":"10.1016\/j.cancergen.2012.12.003_bib37","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1158\/1078-0432.CCR-05-1846","article-title":"Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib","volume":"12","author":"Riely","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cancergen.2012.12.003_bib38","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1136\/jclinpath-2011-200169","article-title":"Comparison of clinical outcome of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations","volume":"64","author":"Won","year":"2011","journal-title":"J\u00a0Clin Pathol"},{"key":"10.1016\/j.cancergen.2012.12.003_bib39","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.lungcan.2009.11.020","article-title":"KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: a meta-analysis of 22 studies","volume":"69","author":"Mao","year":"2010","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cancergen.2012.12.003_bib40","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.prp.2009.07.010","article-title":"Frequency and\u00a0type of KRAS mutations in routine diagnostic analysis of\u00a0metastatic colorectal cancer","volume":"205","author":"Neumann","year":"2009","journal-title":"Pathol Res Pract"},{"key":"10.1016\/j.cancergen.2012.12.003_bib41","series-title":"Textbook of Lung Cancer","first-page":"1","article-title":"Etiology of lung cancer","author":"Haugen","year":"2008"},{"key":"10.1016\/j.cancergen.2012.12.003_bib42","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1093\/carcin\/23.12.1979","article-title":"Smoking-related DNA and protein adducts in human tissues","volume":"23","author":"Phillips","year":"2002","journal-title":"Carcinogenesis"}],"container-title":["Cancer Genetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210776212002785?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210776212002785?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:37:46Z","timestamp":1761896266000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2210776212002785"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1]]},"references-count":42,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2013,1]]}},"alternative-id":["S2210776212002785"],"URL":"https:\/\/doi.org\/10.1016\/j.cancergen.2012.12.003","relation":{},"ISSN":["2210-7762"],"issn-type":[{"value":"2210-7762","type":"print"}],"subject":[],"published":{"date-parts":[[2013,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The dominant role of G12C over other KRAS mutation types in the negative prediction of efficacy of epidermal growth\u00a0factor receptor tyrosine kinase inhibitors in non\u2013small cell\u00a0lung cancer","name":"articletitle","label":"Article Title"},{"value":"Cancer Genetics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cancergen.2012.12.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}